The main purpose of this Manual is to provide useful guidelines for the selection of pathology tests and to facilitate interpretation of results.
Contains a comprehensive listing of all genes from the Human Gene Nomenclature Committee (HGNC) database alongside laboratories and tests available in the country.
A manual for the process of macroscopic dissection in Anatomical Pathology laboratories.
Donate online now using the button below. RCPA Foundation thanks you for your generous support. All funds raised will be allocated to the RCPA Foundation Pathology Education Outreach Fellowship.
Events and Sponsorship Manager
Ph: +61 2 8356 5806
Fax: +61 2 8356 5828
Events and Grants Coordinator
Ph: +61 2 8356 5852
Fax: +61 2 8356 5828
Keywords: Anti Xa, Heparin assay
4.5 mL blood added to 0.5 mL citrate.
When requesting assay, information on current anticoagulant use needs to be specified.
Monitoring is not required for prophylactic dosing.
If monitoring is required for therapeutic dosing, the therapeutic range will differ according to mode and frequency of administration and according to anticoagulant.
Monitoring of (full dose) low molecular weight heparin (LMWH) therapy is not generally required, except in renal failure, extremes of body weight, pregnancy or other situations where there is an increased risk of bleeding. LMWH should be used with care and monitoring in patients with any abnormality of renal function, particularly the elderly. Monitoring should be done in consultation with a haematologist.
Monitoring of routine LMWH prophylaxis is not cost effective, is not required to achieve clinical efficacy and is not indicated to predict risk of bleeding, which is minimal with prophylactic doses in patients with normal renal function.
In consultation with a haematologist or pathologist, may also be used in exceptional circumstances for monitoring of unfractionated heparin, fondaparinux and oral direct Xa inhibitor (rivaroxaban, apixaban) therapy. Therapeutic ranges vary according to the anticoagulant– consult pathologist.
Most patients on low molecular weight heparin, pentasaccharide (fondaparinux) and oral direct Xa inhibitor (rivaroxaban, apixaban) therapy do not require monitoring.
Walenga J et al. Thromb Res 1991; 14: 49-62.
Hirsch J, Levine MN. Blood 1992; 79: 1-17.
Garcia DA1, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e24S-43S
Page last updated:
The RCPA is the leading organisation representing Pathologists and Senior Scientists in Australasia.
Its mission is to train and support pathologists and senior scientists and to improve the use of pathology testing to achieve better healthcare.
The annual scientific meeting for the RCPA which covers the scientific disciplines of Anatomical, Chemical, Forensic, Genetic, General, Haematology, Immunopathology and Microbiology.
Copyright © 2020 RCPA. All rights reserved.